Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development. For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply.
View Top Employees from HemoGenyx LLCWebsite | http://www.hemogenyx.com |
Revenue | $5 million |
Funding | $13.2 million |
Employees | 1 (1 on RocketReach) |
Founded | 2013 |
Address | 4 Lombard St, London, Greater London EC3V 9HD, GB |
Phone | +44 20 7933 8780 |
Industry | Biotechnology, Manufacturing General, Drug Discovery, Manufacturing, Science and Engineering, Health Care, Pharmaceutical |
Web Rank | 16 Million |
Keywords | Hemogenyx Largest Shareholders, Hemogenyx, Hemogenyx-Cell |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular HemoGenyx LLC employee's phone or email?
The HemoGenyx LLC annual revenue was $5 million in 2024.
Elina Shrestha is the Director of Preclinical Development of HemoGenyx LLC.
1 people are employed at HemoGenyx LLC.
HemoGenyx LLC is based in London, Greater London.
The NAICS codes for HemoGenyx LLC are [325, 3254, 32541, 32].
The SIC codes for HemoGenyx LLC are [28, 283].